Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2012 1
2013 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Cilostazol for the prevention of acute progressing stroke: a multicenter, randomized controlled trial.
Shimizu H, Tominaga T, Ogawa A, Kayama T, Mizoi K, Saito K, Terayama Y, Ogasawara K, Mori E; Tohoku Acute Stroke Progressing Stroke Study Group. Shimizu H, et al. J Stroke Cerebrovasc Dis. 2013 May;22(4):449-56. doi: 10.1016/j.jstrokecerebrovasdis.2013.02.009. Epub 2013 Mar 29. J Stroke Cerebrovasc Dis. 2013. PMID: 23541423 Clinical Trial.
A pilot randomized controlled trial was conducted to investigate the effect of cilostazol on progressing stroke. ...The modified Rankin Scale score of 0 to 1 at 3 months did not differ between the groups. CONCLUSIONS: Cilostazol fa …
A pilot randomized controlled trial was conducted to investigate the effect of cilostazol on progressing …
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS. Kwon SU, et al. Stroke. 2005 Apr;36(4):782-6. doi: 10.1161/01.STR.0000157667.06542.b7. Epub 2005 Mar 3. Stroke. 2005. PMID: 15746463 Clinical Trial.
In cilostazol group, 3 (6.7%) of 45 symptomatic IAS progressed and 11 (24.4%) regressed. In placebo group, 15 (28.8%) of symptomatic IAS progressed and 8 (15.4%) regressed. Progression of symptomatic IAS in cilostazol group was significantly low …
In cilostazol group, 3 (6.7%) of 45 symptomatic IAS progressed and 11 (24.4%) regressed. In placebo group, 15 (28.8%) of sympt …
Final Results of Cilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery Stenosis (CATHARSIS).
Uchiyama S, Sakai N, Toi S, Ezura M, Okada Y, Takagi M, Nagai Y, Matsubara Y, Minematsu K, Suzuki N, Tanahashi N, Taki W, Nagata I, Matsumoto M; CATHARSIS Study Group. Uchiyama S, et al. Cerebrovasc Dis Extra. 2015 Jan 15;5(1):1-13. doi: 10.1159/000369610. eCollection 2015 Jan-Apr. Cerebrovasc Dis Extra. 2015. PMID: 25759708 Free PMC article.
PURPOSE: To compare the effect of cilostazol plus aspirin versus aspirin alone on the progression of intracranial arterial stenosis (IAS), and to compare ischemic and hemorrhagic events in patients with symptomatic IAS, an investigator-driven, nationwide multicen …
PURPOSE: To compare the effect of cilostazol plus aspirin versus aspirin alone on the progression of intracranial arterial ste …
Association between changes in lipid profiles and progression of symptomatic intracranial atherosclerotic stenosis: a prospective multicenter study.
Kim DE, Kim JY, Jeong SW, Cho YJ, Park JM, Lee JH, Kang DW, Yu KH, Bae HJ, Hong KS, Koo JS, Lee SH, Lee BC, Han MK, Rha JH, Lee YS, Kim GM, Chae SL, Kim JS, Kwon SU. Kim DE, et al. Stroke. 2012 Jul;43(7):1824-30. doi: 10.1161/STROKEAHA.112.653659. Epub 2012 Apr 26. Stroke. 2012. PMID: 22539545 Clinical Trial.
RESULTS: Cilostazol treatment was more frequently seen in the nonprogression group (109 of 198 [55.1%]) than in the progression group (11 of 32 [34.4%]). ...CONCLUSIONS: This is the first prospective multicenter study to demonstrate that high-density lipoprot …
RESULTS: Cilostazol treatment was more frequently seen in the nonprogression group (109 of 198 [55.1%]) than in the progression …